Safety and Pharmacokinetics of MK‐8527 in Adults Without HIV

ABSTRACT MK‐8527 is a nucleoside reverse transcriptase translocation inhibitor (NRTTI) in clinical development. Two Phase 1 trials evaluated single (trial A) and multiple (trial B) ascending doses of MK‐8527 in adults without HIV. In trial A, 34 participants were assigned to 1 of 4 panels and random...

Full description

Bibliographic Details

Published in:	Clinical and Translational Science
Main Authors:	Gillian Gillespie, Russ P. Carstens, Xiaowei Zang, Ryan Vargo, Yash Kapoor, Arinjita Bhattacharyya, Jean‐Francois Denef, Tom Reynders, Frédéric Vanhoutte, Sylvie Rottey, Randolph P. Matthews, S. Aubrey Stoch, Marian Iwamoto
Format:	Article
Language:	English
Published:	Wiley 2025-09-01
Subjects:	HIV pharmacokinetics Phase 1 safety
Online Access:	https://doi.org/10.1111/cts.70331